In 2013, the Aldosterone Receptor Blockade in Diastolic Heart Failure (ALDO-HF)trial showed that E/e’ and reducedleft ventricular mass in the treatment group (n = 213) compared to the placebo (n= 209), even if it did not benefit the maximal exercise capacity or the patient’ssymptoms and quality of life [77]. Here, NR3C2 is linked to hydrops fetalis.